Demers GW - Search Results

1

Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy.

Ramachandra M, Rahman A, Zou A, Vaillancourt M, Howe JA, Antelman D, Sugarman B, Demers GW, Engler H, Johnson D, Shabram P. Ramachandra M, et al. Among authors: demers gw. Nat Biotechnol. 2001 Nov;19(11):1035-41. doi: 10.1038/nbt1101-1035. Nat Biotechnol. 2001. PMID: 11689848

2

Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy.

Demers GW, Johnson DE, Tsai V, Wen SF, Quijano E, Machemer T, Philopena J, Ramachandra M, Howe JA, Shabram P, Ralston R, Engler H. Demers GW, et al. Cancer Res. 2003 Jul 15;63(14):4003-8. Cancer Res. 2003. PMID: 12873998

3

Tumor growth inhibition by interferon-alpha using PEGylated protein or adenovirus gene transfer with constitutive or regulated expression.

Demers GW, Johnson DE, Machemer T, Looper LD, Batinica A, Beltran JC, Sugarman BJ, Howe JA. Demers GW, et al. Mol Ther. 2002 Jul;6(1):50-6. doi: 10.1006/mthe.2002.0629. Mol Ther. 2002. PMID: 12095303 Free article.

4

Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model.

Tsai V, Johnson DE, Rahman A, Wen SF, LaFace D, Philopena J, Nery J, Zepeda M, Maneval DC, Demers GW, Ralston R. Tsai V, et al. Among authors: demers gw. Clin Cancer Res. 2004 Nov 1;10(21):7199-206. doi: 10.1158/1078-0432.CCR-04-0765. Clin Cancer Res. 2004. PMID: 15534093

5

Suppression of tumorigenicity of glioblastoma cells by adenovirus-mediated MMAC1/PTEN gene transfer.

Cheney IW, Johnson DE, Vaillancourt MT, Avanzini J, Morimoto A, Demers GW, Wills KN, Shabram PW, Bolen JB, Tavtigian SV, Bookstein R. Cheney IW, et al. Among authors: demers gw. Cancer Res. 1998 Jun 1;58(11):2331-4. Cancer Res. 1998. PMID: 9622068

6

Calpain inhibitor 1 activates p53-dependent apoptosis in tumor cell lines.

Atencio IA, Ramachandra M, Shabram P, Demers GW. Atencio IA, et al. Among authors: demers gw. Cell Growth Differ. 2000 May;11(5):247-53. Cell Growth Differ. 2000. PMID: 10845425

7

Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy.

Howe JA, Demers GW, Johnson DE, Neugebauer SE, Perry ST, Vaillancourt MT, Faha B. Howe JA, et al. Among authors: demers gw. Mol Ther. 2000 Nov;2(5):485-95. doi: 10.1006/mthe.2000.0206. Mol Ther. 2000. PMID: 11082322 Free article.

8

Interferon alpha2b gene delivery using adenoviral vector causes inhibition of tumor growth in xenograft models from a variety of cancers.

Iqbal Ahmed CM, Johnson DE, Demers GW, Engler H, Howe JA, Wills KN, Wen SF, Shinoda J, Beltran J, Nodelman M, Machemer T, Maneval DC, Nagabhushan TL, Sugarman BJ. Iqbal Ahmed CM, et al. Among authors: demers gw. Cancer Gene Ther. 2001 Oct;8(10):788-95. doi: 10.1038/sj.cgt.7700364. Cancer Gene Ther. 2001. PMID: 11687902

9

A recombinant adenoviral vector expressing full-length human retinoblastoma susceptibility gene inhibits human tumor cell growth.

Demers GW, Harris MP, Wen SF, Engler H, Nielsen LL, Maneval DC. Demers GW, et al. Cancer Gene Ther. 1998 Jul-Aug;5(4):207-14. Cancer Gene Ther. 1998. PMID: 9694072

10

Interferon-alpha2b secretion by adenovirus-mediated gene delivery in rat, rabbit, and chimpanzee results in similar pharmacokinetic profiles.

Demers GW, Sugarman BJ, Beltran JC, Westreich LN, Ahmed CM, Lau JY, Hong Z, Lanford RE, Maneval DC. Demers GW, et al. Toxicol Appl Pharmacol. 2002 Apr 1;180(1):36-42. doi: 10.1006/taap.2002.9372. Toxicol Appl Pharmacol. 2002. PMID: 11922775

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters